Tru Niagen at GNC and Sam's Club Signals NAD+ Has Left the Longevity Niche
The number one NAD+ supplement in the US is now in nearly 300 retail locations across 44 states. What the GNC and Sam's Club expansion says about where the longevity market is heading.
Wonderfeel: What a 4,235% Growth Rate Signals for the NAD+ Supplement Market
The NAD+ longevity brand ranked No. 1 biotech on the 2026 Inc. 5000. The growth rate reflects a consumer longevity market that's moving faster than most industry observers expected.
The Antiaging Trial That Just Won $1M From XPRIZE to Test in Humans
AgelessRx has been selected as one of 10 Milestone 2 awardees in the $101M XPRIZE Healthspan competition, earning $1M to advance a one-year randomized trial testing a six-component antiaging protocol including low-dose rapamycin, NAD+, and metformin.
Niagen's NR Study: A 2.5-Year Drop in Muscle Epigenetic Age
A new peer-reviewed analysis links NR supplementation to a 2.5-year reduction in muscle epigenetic age — though the funding company calls the data preliminary.
Elysium Health Launches Physician-Led Longevity Program — Moving From Supplements to Clinical Care
Elysium's new Elysium Longevity Institute combines NAD+ protocols, peptides, and longitudinal data tracking under physician oversight. The shift signals a broader move in longevity from consumer supplementation to integrated clinical programs.
Niagen Plus: Why the NAD+ Market Just Went Injectable
Niagen Bioscience's $299 at-home injection kit delivers pharmaceutical-grade NR subcutaneously — bypassing gut metabolism. What the biohacking shift to injectables signals.
Peter Attia AMA #84: Family History, NAD Skepticism, and Dementia Risk
Peter Attia AMA #84: why family health history outperforms genetic testing, his stance on NAD supplements, and minimum effective strength training dose.
NR Sales Hit $129M: What Niagen Bioscience's 30% Growth Signals About the NAD+ Market
Niagen Bioscience reported $129.4M in 2025 revenue — up 30% — with net income more than doubling. The NAD+ precursor category is no longer a niche bet.